Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseasesPfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumorsAcepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapiesALAMEDA, Calif. and TAIPEI, Sept. 3, 2024 /PRNews ...